RATIONALE: Early diagnosis of bronchiolitis obliterans syndrome (BOS) is critical in understanding pathogenesis and devising therapeutic trials. Although potential-BOS stage (BOS 0-p), encompassing early changes in FEV(1) and forced expiratory flow, midexpiratory phase (FEF(25-75%)), has been proposed, there is a paucity of data validating its utility in single-lung transplantation. OBJECTIVE: The aim of this study was to define the predictive ability of BOS 0-p in single-lung transplantation. METHODS: We retrospectively analyzed spirometric data for 197 single-lung recipients. Sensitivity, specificity, and positive predictive value of BOS 0-p were examined over time using Kaplan-Meier methodology. RESULTS: BOS 0-p FEV(1) was associated with higher sensitivity, specificity, and positive predictive value than the FEF(25-75%) criterion over different time periods investigated. The probability of testing positive for BOS 0-p FEV(1) in patients with BOS (sensitivity) was 71% at 2 years before the onset of BOS. The probability of being free from development of BOS 0-p FEV(1) in patients free of BOS at follow-up (specificity) was 93% within the last year. Of patients who met the BOS 0-p FEV(1) criterion, 81% developed BOS or died within 3 years. The specificity and positive predictive value curves for the BOS 0-p FEV(1) were significantly different between patients with underlying restrictive versus obstructive physiology (p = 0.05 and 0.01, respectively). CONCLUSION: The FEV(1) criterion for BOS 0-p provides useful predictive information regarding the risk of development of BOS or death in single-lung recipients. The predictive value of this criterion is higher in patients with underlying restriction and is superior to the FEF(25-75%) criterion.
RATIONALE: Early diagnosis of bronchiolitis obliterans syndrome (BOS) is critical in understanding pathogenesis and devising therapeutic trials. Although potential-BOS stage (BOS 0-p), encompassing early changes in FEV(1) and forced expiratory flow, midexpiratory phase (FEF(25-75%)), has been proposed, there is a paucity of data validating its utility in single-lung transplantation. OBJECTIVE: The aim of this study was to define the predictive ability of BOS 0-p in single-lung transplantation. METHODS: We retrospectively analyzed spirometric data for 197 single-lung recipients. Sensitivity, specificity, and positive predictive value of BOS 0-p were examined over time using Kaplan-Meier methodology. RESULTS:BOS 0-p FEV(1) was associated with higher sensitivity, specificity, and positive predictive value than the FEF(25-75%) criterion over different time periods investigated. The probability of testing positive for BOS 0-p FEV(1) in patients with BOS (sensitivity) was 71% at 2 years before the onset of BOS. The probability of being free from development of BOS 0-p FEV(1) in patients free of BOS at follow-up (specificity) was 93% within the last year. Of patients who met the BOS 0-p FEV(1) criterion, 81% developed BOS or died within 3 years. The specificity and positive predictive value curves for the BOS 0-p FEV(1) were significantly different between patients with underlying restrictive versus obstructive physiology (p = 0.05 and 0.01, respectively). CONCLUSION: The FEV(1) criterion for BOS 0-p provides useful predictive information regarding the risk of development of BOS or death in single-lung recipients. The predictive value of this criterion is higher in patients with underlying restriction and is superior to the FEF(25-75%) criterion.
Authors: Marc Estenne; Janet R Maurer; Annette Boehler; James J Egan; Adaani Frost; Marshall Hertz; George B Mallory; Gregory I Snell; Samuel Yousem Journal: J Heart Lung Transplant Date: 2002-03 Impact factor: 10.247
Authors: Elbert P Trulock; Leah B Edwards; David O Taylor; Mark M Boucek; Paul J Mohacsi; Berkeley M Keck; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2003-06 Impact factor: 10.247
Authors: Ramsey R Hachem; Murali M Chakinala; Roger D Yusen; John P Lynch; Aviva A Aloush; G Alexander Patterson; Elbert P Trulock Journal: Am J Respir Crit Care Med Date: 2003-12-11 Impact factor: 21.405
Authors: M I Hertz; C A Henke; R E Nakhleh; K R Harmon; W A Marinelli; J M Fox; S H Kubo; S J Shumway; R M Bolman; P B Bitterman Journal: Proc Natl Acad Sci U S A Date: 1992-11-01 Impact factor: 11.205
Authors: Natalie M Walker; Linda N Badri; Anish Wadhwa; Scott Wettlaufer; Marc Peters-Golden; Vibha N Lama Journal: Am J Respir Crit Care Med Date: 2012-01-01 Impact factor: 21.405
Authors: Sameem Abedin; Gregory A Yanik; Thomas Braun; Attaphol Pawarode; John Magenau; Steven C Goldstein; John E Levine; Carrie L Kitko; Daniel R Couriel Journal: Biol Blood Marrow Transplant Date: 2015-02-14 Impact factor: 5.742
Authors: John R Greenland; Kirk D Jones; Steve R Hays; Jeffrey A Golden; Anatoly Urisman; Nicholas P Jewell; George H Caughey; Neil N Trivedi Journal: Am J Respir Crit Care Med Date: 2012-12-13 Impact factor: 21.405
Authors: S Samuel Weigt; Ariss DerHovanessian; W Dean Wallace; Joseph P Lynch; John A Belperio Journal: Semin Respir Crit Care Med Date: 2013-07-02 Impact factor: 3.119
Authors: Guang-Shing Cheng; Barry Storer; Jason W Chien; Madan Jagasia; Jesse J Hubbard; Linda Burns; Vincent T Ho; Joseph Pidala; Jeanne Palmer; Laura Johnston; Sebastian Mayer; Kristina Crothers; Iskra Pusic; Stephanie J Lee; Kirsten M Williams Journal: Ann Am Thorac Soc Date: 2016-11